Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5827342 | European Journal of Pharmacology | 2015 | 8 Pages |
Abstract
Ï2 Receptor subtype is overexpressed in a variety of human tumors, with Ï2 agonists showing antiproliferative effects towards tumor cells through multiple pathways that depend both on the tumor cell type and on the molecule type. Therefore, Ï2 receptor is an intriguing target for tumor diagnosis and treatment despite the fact that that it has not yet been cloned. One of the last attempts to characterize Ï2 receptors led to identify it as the progesterone receptor membrane component 1 (PGRMC1). Although still controversial, such identity appears to have been accepted. We the aim of contributing to solve this controversy, in this work we stably silenced or overexpressed PGRMC1 protein in human MCF7 adenocarcinoma cells. Western blotting analyses were performed to quantify the presence of PGRMC1 protein on each of the three MCF7 cell lines variants, while scatchard analyses with radioligand were performed in order to determine the expression of the Ï2 receptors. In order to correlate the antiproliferative effect of Ï2 receptor agonist with PGRMC1 density, some Ï2 ligands were administered to each of the three MCF7 cells variants. The results suggested that PGRMC1 and Ï2 receptors are two different molecular entities.
Keywords
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Carmen Abate, Mauro Niso, Vittoria Infantino, Alessio Menga, Francesco Berardi,